Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction

Patent metadata

Field	Value
Publication number	US-9241967-B2
Application number	US-200913002638-A
Country	US
Kind code	B2
Filing date	Jul 9, 2009
Priority date	Jul 9, 2008
Publication date	Jan 26, 2016
Grant date	Jan 26, 2016

Abstract

The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, wherein an amino-terminal residue of the peptide is N-alkylated. Alternatively the compound of the invention comprises a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, where the first and second peptide or peptide analogue each comprise at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof.

First claim

The invention claimed is:

1. A compound comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a PEG linker comprising 4 to 6 moieties (N=4-6) of ethylene glycol, wherein said linker is associated with a N-terminus of said first and second peptide or peptide analogue, and wherein said first and said second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence SEQ ID NO: 25 or SEQ ID NO: 26, wherein
a. Xaa 1 is selected from among E, Q, and A, or an analogue thereof, and
b. Xaa 3 is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof.

2. The compound of claim 1 , wherein at least one of the peptide or peptide analogues is N-alkylated in position p −3 in the sequence.

3. The compound of claim 1 , capable of inhibiting a protein-protein interaction between NMDAR and PSD-95.

4. The compound according to claim 1 , wherein the peptide or peptide analogue is from 4 to 10 amide-bonded residues in length.

5. The compound according to claim 4 , wherein the peptide is comprised of at least 4 L-amino acid residues.

6. The compound according to claim 5 , wherein Xaa 3 is selected from among A, Q, and D.

7. The compound according to claim 1 , wherein the peptide or peptide analogue is N-alkylated with a cyclohexane substituent, and further comprises a spacer group between the substituent and the terminal amino group of the peptide or peptide analogue, wherein the spacer is an alkyl group, preferably selected from among methylene, ethylene, propylene and butylene.

8. The compound according to claim 1 , wherein the peptide or peptide analogue is N-alkylated with an aromatic substituent, and further comprises a spacer group between the substituent and the terminal amino group of the peptide, wherein the spacer is an alkyl group, preferably selected from among methylene, ethylene, propylene and butylene.

9. The compound according to claim 8 , wherein the aromatic substituent is a naphthalen-2-yl moiety.

10. The compound according to claim 8 , wherein the aromatic substituent is an aromatic ring substituted with one or two halogen and/or alkyl groups.

11. The compound according to claim 1 , wherein at least one of the peptides or peptide analogues is covalently bonded to a polyamine or a diamine.

12. A method of inhibiting a protein-protein interaction between a protein and a PDZ domain, comprising contacting the PDZ domain with the compound of claim 1 .

13. The method according to 12 , wherein said interaction is between an NMDAR and PSD-95 and wherein the NMDAR is comprised in a cell.

14. A pharmaceutical composition comprising the compound of claim 1 .

15. A kit comprising the pharmaceutical composition according to claim 14 , further comprising means for delivering said composition to a subject.

16. A method of treating or providing prophylaxis against an excitotoxic-related disease in a subject, comprising administering a compound to a subject in need thereof, wherein said disease is ischemic or traumatic injury of the CNS, said compound comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a PEG linker comprising 1 to 12 moieties (N=1-12) of ethylene glycol wherein said first and said second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence SEQ ID NO: 25 or SEQ ID NO: 26, wherein
a. Xaa 1 is selected from among E, Q, and A, or an analogue thereof, and
b. Xaa 3 is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof.

17. The method according to claim 16 , wherein the linker comprises 4 to 6 moieties (N=4-6) of ethylene glycol.

18. The method according to claim 16 , wherein the linker comprises 8 to 12 moieties (N=8-12) of ethylene glycol.

Assignees

• Bach Anders
• Stromgaard Kristian
• Univ Copenhagen

Inventors

• Bach Anders
• Stromgaard Kristian

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K5/1008

  the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala · CPC title

• C07K14/70571

  for neuromediators, e.g. serotonin receptor, dopamine receptor · CPC title

• A61K38/07 Primary

  Tetrapeptides · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title